Abstract C7: Targeting the androgen receptor with novel combination therapeutic strategies in metastatic/castrate-resistant prostate cancer

While recent advances have resulted in the FDA approval of novel therapies for metastatic/castrate resistant prostate cancer, responses are not often durable and novel therapeutic interventions are still required. Recent work within our laboratory has resulted in the development of a novel orthotopic syngeneic transplant mouse model of prostate cancer. Further, treatment with a HDAC and mTORC1 inhibitor in combination resulted in greater anti-tumor and increased overall survival in tumor bearing animals. HDAC/mTORC1 combination therapy also resulted in decreased androgen receptor (AR) transcriptional activity without loss of AR protein expression. Current investigations are underway to delineate molecular mechanisms underlying sustained AR expression. Through this understanding, novel therapeutic interventions which will augment combined HDAC/mTORC1 inhibitor therapy are under investigation. Citation Format: Leigh Ellis, Swathi Ramakrishnan, Shengyu Ku, Roberto Pili. Targeting the androgen receptor with novel combination therapeutic strategies in metastatic/castrate-resistant prostate cancer [abstract]. In: Proceedings of the AACR Special Conference on Advances in Prostate Cancer Research; 2012 Feb 6-9; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2012;72(4 Suppl):Abstract nr C7.